Navigation Links
Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
Date:9/26/2007

COLORADO SPRINGS, Colo., Sept. 26 /PRNewswire-FirstCall/ -- Spectranetics Corporation (Nasdaq: SPNC) today announced it has enrolled the first patient in the PATENT trial utilizing the Company's TURBO elite(TM) laser catheters in combination with the recently FDA cleared TURBO-Booster(TM).

The PATENT trial is a prospective registry of 100 patients at up to 10 sites in Germany. The trial will assess patency as measured by duplex ultrasound at various intervals up to 12 months following the procedure. It will also assess safety as measured by adverse events up to 12 months following the procedure. In the initial procedure performed at the Leipzig Heart Center, four focal lesions were treated successfully with the TURBO-Booster and TURBO elite 2.0mm catheter in a 20cm long stented superficial femoral artery.

"The initial result from this Spectranetics device looks very promising, as the new features allow for ablation of more tissue in larger vessels," said Andrej Schmidt, M.D., of the University of Leipzig-Heart Center. "Instent restenosis in a superficial femoral artery represents one of the most challenging procedures in our practice. The current standard of care, such as repeat balloon angioplasty, does not have good results as these lesions tend to reoccur. We are very excited with the start of this study in Germany, and we look forward to examining the mid- and long-term results of this new therapy."

John G. Schulte, Spectranetics' President and Chief Executive Officer, commented, "We are very pleased to have begun this trial at one of Europe's most prestigious medical centers. We believe that instent restenosis in the superficial femoral artery may represent 25% to 35% of all above-the-knee proce
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... 2015 Increasing sophistication among enterprise buyers of language ... in 2015, says Moravia CMO, Renato ... by market research firm Common Sense Advisory, 15 percent ... translation and localization needs. "From a language industry perspective, ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Feb. 28, 2011 PolyOne Corporation (NYSE: POL ... in SunBelt Chlor Alkali Partnership to Olin Corporation.   ... venture formed in 1996 between PolyOne (formerly The Geon Company) ... for $175 million, including $132 million in cash and the ...
... LOUIS, Feb. 28, 2011 Stereotaxis, Inc. (Nasdaq: ... full year and fourth quarter ended December 31, 2010. ... capital orders, record recurring revenue and record gross margins. ... the year, which helped to drive decreases in both ...
Cached Medicine Technology:PolyOne Announces Sale of SunBelt Investment 2PolyOne Announces Sale of SunBelt Investment 3Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 2Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 3Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 4Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 5Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 6Stereotaxis Reports 2010 Financial Results, Provides 2011 Financial Outlook 7
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... National,Organization of Life & Health Insurance Guaranty Associations ... that are playing,a central role in the resolution ... of New York (ELNY) matter., NOLHGA President ... ELNY situation: "NOLHGA and all of our member ...
... bleeding risk for patients undergoing bypass, study finds , , ... of anticlotting drug is safe over the long run ... , The drug, a "direct thrombin inhibitor" called bivalirudin, ... procedures such as bypass surgery. , "We had a ...
... to outlive folks who aren,t, study finds , , TUESDAY, Dec. ... life, a new study suggests fit is where it,s at ... who were physically fit outlived their contemporaries -- even thin ... fitness is a strong determinate of mortality in older men ...
... BMIs experience a significant survival benefit from liver ... transplant compared to patients with normal BMI. Therefore, ... listed for transplantation, say the authors of a ... a journal by John Wiley & Sons. The ...
... New Orleans residents in months after the disaster, study found ... people living in New Orleans and about one-quarter of those ... of a mood or anxiety disorder five to seven months ... surveyed 1,043 residents in Louisiana, Alabama and Mississippi. , They ...
... 3 LIVES or PROVIDE A LIFETIME OF, CLEAN, ... simple., NEW YORK, Dec. 4 This December, TONIC ... T-Shirts, designed,by guest designers., TONIC is a refreshing company ... planet through offering services and,products. Each is designed to aid ...
Cached Medicine News:Health News:Statement on Executive Life of New York Matter 2Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 2Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 3Health News:Fitness, Not Fatness, Predicts a Longer Life 2Health News:Liver transplant offers survival benefits for patients of all sizes 2Health News:Liver transplant offers survival benefits for patients of all sizes 3Health News:Many Katrina Survivors Suffered Psychological Symptoms 2Health News:TONIC Announces Every T Counts Project 2Health News:TONIC Announces Every T Counts Project 3
...
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... The Consensus knee system continues the ... intelligent engineering with the diversified experience of ... an affordable knee system that incorporates state-of-the-art ... provide both joint and implant stability and ...
Medicine Products: